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Abstract
Background: The National Institute for Health and Care Excellence (NICE) recommends that Cognitive Behaviour
Therapy for psychosis (CBTp) is offered to all patients with a psychosis diagnosis. However, only a minority of
psychosis patients in England and Wales are offered CBTp. This is attributable, in part, to the resource-intensive
nature of CBTp. One response to this problem has been the development of CBTp in brief formats that are targeted
at a single symptom and the mechanisms that maintain distress. We have developed a brief form of CBTp for
distressing voices and reported preliminary evidence for its effectiveness when delivered by highly trained
therapists (clinical psychologists). This study will investigate the delivery of this intervention by a cost-effective
workforce of assistant psychologists following a brief training and evaluate the acceptability and feasibility of
conducting a future, definitive, randomised controlled trial (RCT).
Methods: This is a feasibility study for a pragmatic, three-arm, parallel-group, superiority 1:1:1 RCT comparing a
Guided self-help CBT intervention for voices and treatment as usual (GiVE) to Supportive Counselling and treatment
as usual (SC) to treatment as usual alone (TAU), recruiting across two sites, with blinded post-treatment and follow-
up assessments. A process evaluation will quantitatively and qualitatively explore stakeholder experience.
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Discussion: Expected outcomes will include an assessment of the feasibility of conducting a definitive RCT, and
data to inform the calculation of its sample size. If evidence from a subsequent, fully powered RCT suggests that
GiVE is clinically and cost-effective when delivered by briefly trained assistant psychologists, CBTp offered in these
less resource-intensive forms has the potential to generate benefits for individual patients (reduced distress,
enhanced recovery and enhanced quality of life), service-level patient benefit (increased access to evidence-based
psychological therapies) and economic benefits to the NHS (in terms of the reduced use of mental health inpatient
services).
Trial registration: Current Controlled Trials, ISRCTN registration number: 16166070. Registered on 5 February 2019.
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Introduction {6a}
Cognitive Behaviour Therapy for psychosis (CBTp) has
robust evidence for clinical [1–3] and cost-effectiveness
[4] and is recommended by the National Institute for
Health and Care Excellence (NICE) to promote the re-
covery of psychosis patients [4]. However, implementa-
tion in the UK is extremely poor [5], with only 26% of
psychosis patients being offered CBTp [6]. The most
consistently reported barrier to implementation is insuf-
ficient resources, including a lack of trained therapists
with dedicated time to deliver CBTp [7].
The Department of Health’s Forward View for
Mental Health [8] and Long Term Plan [9] include a
commitment to increase access to evidence-based
psychological therapies for patients with psychosis.
However, future investments in additional trained
therapists with dedicated time to deliver CBTp are
unlikely to be made on a large enough scale to sig-
nificantly and comprehensively increase access to
CBTp in the near future. Consequently, additional
strategies for increasing access may be required, in-
cluding a reduction in the resources required to de-
liver CBTp.
NICE [4] recommend research into two issues that
could potentially reduce the resources required to
deliver CBTp. Firstly, the duration of CBTp – how many
sessions are required to generate sufficient benefit? Our
meta-analysis of 10 controlled studies indicated that
CBTp delivered over less than the recommended 16 ses-
sions is effective in reducing psychosis symptoms when
delivered by trained therapists (typically clinical psychol-
ogists) [10]. This focus upon shorter forms of CBTp has
recently been taken forward through the development of
single-symptom therapies [11] which target only one
specific psychotic symptom, with some promising early
results [12–15]. Sepsychosis patients and the
NHS.condly, the ability of ‘briefly trained’ practitioners
to deliver CBTp – can CBTp be delivered by a more cost
effective alternative workforce (i.e. not highly trained
therapists)? Evidence to date suggests that case managers
cannot fulfil this role as outcomes from trials have been
inconclusive [16–19] and there are competing demands
upon their time [18, 19]. Psychology graduates, however,
are well-positioned to undertake such a role [18, 20] as
there is a large number of psychology graduates in the
UK, the USA and elsewhere; their degree provides them
with training in psychological models of emotion and
behaviour; and they can be readily employed in assistant
psychologist (AP) roles at lower cost than more special-
ist therapists.
Our response to the questions posed by NICE was to
develop a brief form of CBTp targeted at distressing
voices. We collaborated with Lived Experience
Consultants to turn our self-help CBT book
(Overcoming Distressing Voices [21]) into a Guided self-
help CBT intervention package (GiVE) supported by a
workbook. Our first step was to demonstrate the validity
and viability of the GiVE intervention package, confirm-
ing that it can be delivered by expert therapists with
benefits for patients. We conducted a pilot randomised
controlled trial (RCT) of GiVE compared to usual care
(N = 28) [22]. Results were encouraging with high levels
of retention within the study (96%), and a very large
between-groups effect for the pre-determined primary
outcome of negative voice impact (d = 1.78) [23].
Our second step within this current study will be to
assess the feasibility of conducting a RCT to evaluate the
outcomes of GiVE when it is delivered by briefly trained
APs. If found to be feasible, the definitive RCT will form
the third step within our programme of research. If
GiVE is found to be clinically and cost-effective in a fu-
ture definitive RCT when delivered by APs, it could sub-
stantially increase the number of psychosis patients who
are able to access CBTp, which will generate benefits for
psychosis patients and the NHS.
Objectives {7}
The long-term aim of this programme of research is to
increase access to CBTp for psychosis patients. This aim
will be achieved if a brief and targeted CBTp interven-
tion delivered by a less costly workforce of briefly
trained APs is found to be clinically and cost-effective.
The specific aim of the current study is to explore
the feasibility of conducting a three-arm RCT of
GiVE delivered by APs. A process evaluation, using
mixed methods and drawing on Normalisation
Process Theory [24], will be used to explore mecha-
nisms and contextual factors that may affect the fu-
ture uptake and implementation of the intervention,
in both research and clinical contexts.
Specifically, this feasibility study aims to assess: (1)
the acceptability of the brief and targeted intervention
to clinicians (will they refer patients to the study?);
(2) the acceptability of the brief and targeted
intervention to patients (can patients be recruited and
retained, and what are their experiences of the
intervention?); and (3) the ability of APs to adhere to
the therapy and clinical supervision protocols. We
will also estimate the standard deviation of outcomes
in order to facilitate a sample size calculation for use
within a definitive trial.
Trial design {8}
This is a feasibility RCT with a three-arm, parallel-group, su-
periority 1:1:1 allocation, comparing a Guided self-help CBT
intervention for Voassessments will be conductedicEs and
treatment as usual (GiVE) to Supportive Counselling and
treatment as usual (SC) to treatment as usual alone (TAU),
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recruiting across two sites, with blinded post-treatment and
follow-up assessments. Outcomes will be assessed at base-
line (pre-randomisation – Time 0), 16weeks (post interven-
tion – Time 1) and 28weeks1 (follow-up – Time 2). Time 1
and 2 assessments will be conducted by a researcher who is
blind to group allocation. Adherence to the therapy protocol
will be assessed by APs after each session. AP competence
will be assessed by independent raters reviewing a random
selection of early, middle- and late-recorded sessions.
A mixed-methods process evaluation drawing upon
Normalisation Process Theory [24] will be used to
capture participants’, clinicians’ and APs’ experiences
of the study and the interventions (GiVE and SC),
and their views on the facilitators and barriers to the
implementation of GiVE within routine psychosis care
pathways. The results will be used to develop logic
models for a future definitive trial and for NHS
implementation.
Methods: participants, interventions and outcomes
Study setting {9}
Participants will be recruited from two sites within the
UK National Health Service (NHS) – Sussex Partnership
NHS Foundation Trust and Pennine Care NHS
Foundation Trust.
Eligibility criteria {10}
Inclusion criteria:
1) Aged 16 years or older
2) In contact with Secondary Care Mental Health
Services (under the care of a consultant psychiatrist)
3) Experiencing current voice-hearing; this will be
operationalised by participants having a score of
at least 1 on item 1 (How frequently did you
hear a voice or voices?) on the Hamilton
Programme for Schizophrenic Voices Question-
naire (HPSVQ) [25] – indicating that the partici-
pant has experienced at least one episode of
voice-hearing in the past week
4) Distressed by hearing voices; operationalised by
participants scoring at least 8 out of 16 on the
‘negative impact’ scale of the HPSVQ [25]
5) Meeting DSM-5 research criteria for Schizophrenia
Spectrum or Other Psychotic Disorders (assessed
by the Structured Clinical Interview for DSM-5 dis-
orders, SCID-5 [26])
6) Willing and able to provide written, informed consent
Exclusion criteria:
1) Established organic cause for distressing voices (e.g.
brain disease or injury)
2) Primary diagnosis of substance misuse
3) Currently detained in hospital under a section of
the Mental Health Act
4) Have completed a full course (minimum of 16 h) of
CBT for psychotic symptoms during the past year
5) Be currently participating, or be confirmed to
participate in another interventional study in which
they are receiving an intervention which utilises
psychological therapy
6) Non-English speaking to the degree that the
participant is unable to fully understand and answer
assessment questions or give informed consent
7) Severe learning disability – assessed using the Test
of Premorbid Functioning – UK (TOPF-UK) [27]
8) Immediate and serious risk to self or other (assessed
at the point of referral/eligibility review)
Who will take informed consent? {26a}
Once a formal referral has been received by the research
team, the potential participant will be contacted to discuss
the study further and arrange a consent and eligibility
meeting with a member of the research team. The
potential participant will have a copy of the Participant
Information Sheet (PIS) at least 24 h before the consent
and eligibility meeting takes place, so they will have time
to read the information, discuss it with friends and family,
and formulate any questions that they may have.
Interventions
Explanation for the choice of comparators {6b}
A three-arm RCT was chosen to enable: (1) any effect of
GiVE to be differentiated from two other components of
the response to talking therapies (the concerned atten-
tion and generic therapeutic effects – both available
within SC); and (2) an evaluation of the cost-
effectiveness of GiVE – generated by a comparison to
the treatments that are usually offered to patients (avail-
able within TAU).
Intervention description {11a}
Guided self-help intervention for Voices (GiVE)
The GiVE intervention will be delivered by an AP and
will follow a workbook [28] that is based upon the
Overcoming Distressing Voices [21] self-help book. Par-
ticipants will be given a copy of both the workbook and
the self-help book at the commencement of therapy by
the AP and asked to engage in some level of self-help
(homework); this will take the form of reading chapters
from the self-help book between therapy sessions and
engaging with the suggested activities within the
1This assessment will only be offered to participants who reach the 28
weeks’ post-randomization milestone before the end of the data collec-
tion period.
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workbook. Participants in the GiVE intervention will
also have the opportunity to access the ‘CHOICES’ mo-
bile phone application.
After an introductory session on coping, the intervention
will cover three core modules: (1) beliefs about the self, (2)
beliefs about voices and (3) relationships. Modules (1) and
(2) draw upon psychoeducation and cognitive behavioural
strategies to help participants to re-evaluate their negative
or unhelpful beliefs related to the self and voices. Module
(3) additionally involves work on how to relate to others
and voices more assertively. GiVE will be delivered over
eight sessions offered over a maximum of 16 weeks. Ses-
sions may be delivered in NHS clinics, participants’ own
homes and other community locations as preferred and
appropriate. Each session will last for up to 1 h, and ses-
sions will be held weekly where possible (16 weeks are
given for the eight sessions to allow for periods of absence,
illness, holidays, etc.). Participants in the GiVE arm will
continue to receive their usual treatment throughout their
participation in the study.
Supportive Counselling (SC)
The SC intervention will follow the therapy protocol that
was used by APs in the full RCT of AVATAR Therapy for
distressing voices [29]. It will be delivered over the same
number and duration of sessions as GiVE, with the aim of
matching the duration of total therapist contact time
across both arms. SC will offer a supportive and non-
judgemental space for the discussion of topics and issues
determined by the participant. The SC therapy protocol
contains specific guidance for the AP on how to respond
to participant disclosure of distressing voices in a manner
that does not provide specific intervention strategies.
The intervention will involve eight sessions over a
maximum of 16weeks. Each session will last for up to 1 h,
and sessions will be held weekly where possible (16weeks
are given for the eight sessions to allow for periods of
absence, illness, holidays, etc.). Sessions may be delivered in
NHS clinics, participants’ own homes and other community
locations as preferred and appropriate. Participants in the
SC arm will continue to receive their usual treatment
throughout their participation in the study.
The same APs will deliver GiVE and SC in order to
minimise the influence of therapist effects; for example,
differing levels of therapist competence. They will receive
a 5-day training in GiVE and SC (one introductory day, 2
days on GiVE and 2 days on SC), delivered by experienced
clinical psychologists and an experienced counselling
psychologist, respectively. Weekly clinical supervision will
be provided by these clinical/counselling psychologists.
Treatment-as-usual
TAU will be provided by the usual care team. TAU
should be informed by NICE guidelines (NICE) [4] and
typically include medication management and support
and monitoring provided by the Adult Mental Health or
Early Intervention in Psychosis Services, with individual
and family psychological therapies offered occasionally.
Strategies to improve adherence to interventions {11c}
Therapeutic drift and contamination will be minimised by
the use of highly detailed therapy protocols and close
supervision of the APs by experienced clinical/counselling
psychologists. Adherence to therapy protocols will be
assessed through APs completing a checklist at the
conclusion of each session. The competence of AP
delivery of the interventions will be assessed by the rating
of session recordings. All therapy sessions will be audio-
recorded (with the participant’s permission) and a random
10% sample rated for competence by independent experts
(a clinical psychologist for GiVE and a counselling psych-
ologist for SC). GiVE sessions will be rated using the Cog-
nitive Therapy Rating Scale for Psychosis [30]. SC sessions
will be rated using the Counselling Adherence Scale [29].
Relevant concomitant care permitted or prohibited
during the trial {11d}
Participants in all three arms of the trial will be
encouraged to engage in, and continue with, existing
treatments. Our methodological approach will be to
carefully monitor and capture the service contacts
received across a range of services in all three arms of
the trial using an adapted version of the Client Service
Receipt Inventory (CSRI) [31]. Within a future definitive
RCT, this will allow us to standardise current practice by
providing all referrers with a best practice manual for
standard treatment which summarises good practice.
Outcomes {12}
The assessment of feasibility will include the calculation
of the number and proportion of: care co-ordinators
(CCs) willing to refer their patients; referred patients
found to be eligible; consenting participants who are
retained within the study and offer full datasets; non-
missing items for each variable; consenting participants
within the GiVE and SC arms who reach the point of
therapy ‘exposure’ (attended at least six of eight therapy
sessions). Feasibility assessment will also measure ther-
apist adherence to therapy and supervision protocols.
Participant timeline {13}
Figure 1 illustrates the trial/recruitment flowchart.
Sample size {14}
Following recommendations [32] for designing feasibility
trials that aim to detect a small-medium standardised effect
size (where the definitive trial will be designed with 90%
power and two-sided 5% significance), this study aims to
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recruit 90 patients [33, 34]. Participants will be in contact
with Community Secondary Care Adult Mental Health Ser-
vices or Early Intervention in Psychosis Services at the time
of consent, across two sites in the UK: (1) Sussex Partnership
NHS Foundation Trust (suburban and rural); and (2) Pen-
nine Care NHS Foundation Trust (suburban and urban).
Recruitment {15}
Participants will be recruited through referrals from the
CCs of psychosis patients (or other appropriate members of
the clinical team) in the host sites. When first approached
about the study by a research assistant (RA), all CCs will be
given a PIS and referral forms. CCs will be asked to share
the PIS with any patients who are potentially eligible for the
study. If a patient shows an interest in the study and gives
their verbal agreement to be contacted by a researcher, the
CC will be asked to complete a referral form.
An additional recruitment strategy at the Sussex site
will involve the use of the Everyone Counts scheme.
Sussex Partnership NHS Foundation Trust has the
Fig. 1 Trial/recruitment flowchart
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Everyone Counts scheme in place for consent to contact
about research opportunities. Members of the Research
and Development Department will contact potentially
eligible patients to discuss the study and invite them to
take part. Interested patients will be able to contact
either the Research and Development Department or the
research team directly and enquire about the study.
They will be invited to discuss the study with their CC
who can then complete a referral form. The research
team could support potential participants to discuss the
study with their CC if this is needed. An additional
strategy will be used in Pennine Care NHS Foundation
Trust, whereby patients who have participated in other
trials within the Trust and have given consent to be
contacted about future studies may be contacted.
Assignment of interventions: allocation
Sequence generation {16a} and concealment mechanism {16b}
Participants will be randomly allocated using the Sealed
Envelope online service https://www.sealedenvelope.
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure
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com/. The trial statistician will set up and test the
randomisation procedure incorporating stratification by
site (Sussex or Pennine) and type of service (Community
Mental Health Team or Early Intervention in Psychosis)
using random block lengths and 1:1:1 allocation.
Participants will be randomly allocated to receive either
the study intervention and treatment as usual (GiVE) or
the control intervention and treatment as usual (SC) or
treatment as usual alone (TAU).
Implementation {16c}
Consented participants will be randomised by the trial
manager using Sealed Envelope. An unblinded
member of the research team will then contact the
participant by telephone to inform them of their
group allocation. APs will be notified by the trial
manager about the participants who are allocated
GiVE and SC and will be asked to arrange a first
appointment, if possible, within 2 weeks following the
randomisation. A letter will be sent to all participants
to confirm their allocation and details of their next
appointment with either the AP (GiVE or SC) or
researcher (TAU). This letter will ask participants not
to disclose their allocation to the researcher.
Assignment of interventions: blinding
Who will be blinded? {17a}
The RAs and the trial statistician will be blind to the
allocation sequence. Following the baseline
assessment, participants will be randomised using
Sealed Envelope and allocated to one of the three
trial arms. Only the trial manager will receive this
notification and will communicate the allocation to all
unblinded members of the research team. Researchers
will be blinded to the allocation and will remain
blinded for all future assessments with the
participants (16-week and 28-week data collection).
Measures to maintain blinding will include: (1) partic-
ipants being reminded at the beginning of each as-
sessment interview to not disclose the group to which
they have been allocated; (2) blinded members of the
research team being shielded from discussion of par-
ticipants in forums where the possibility of determin-
ing participant allocation could occur; (3) researcher
access to electronic health records being restricted;
and (4) consideration given to office allocation and all
administrative processes of blinded-vs-unblinded
members of the research team. ‘Blind’ awareness and
education will be promoted throughout the study. To
test the success of blinding, the blind RA who as-
sesses each participant will be asked to guess the allo-
cation group for each participant at the end of the
final assessment.
Procedure for unblinding if needed {17b}
Reported breaks in blinding will be recorded. Outcome
assessments will be re-blinded by re-allocating ‘blind’
RAs to collect and score study data wherever possible.
Data collection and management
Plans for assessment and collection of outcomes {18a}
See Fig. 2 for details of the assessment at each visit.
Screening measures
The assessment of eligibility in relation to the inclusion
and exclusion criteria will be supported by the use of the
Structured Clinical Interview for DSM-5 Disorders
(SCID-5) [26], the Test of Premorbid Functioning–UK
(TOPF-UK) [27] and the Hamilton Programme for
Schizophrenia Voices Questionnaire (HPSVQ) [25] (each
described below).
Clinical measures – Primary
The primary outcome for a potential future definitive
RCT is the self-reported impact of voice-hearing upon
the participants. Two measures will be evaluated as can-
didates for the primary outcome to be used in a future
definitive RCT:
Psychotic Symptoms Rating Scale (PSYRATS-AH) [35]
Distress Scale – PSYRATS-AH is an 11-item rating scale
designed to measure the severity of different dimensions
of the voice-hearing experience. Items are grouped to-
gether in four factors [36]; distress (negative content,
distress and control), frequency (frequency, duration and
disruption), attribution (location and origin of voices)
and loudness (loudness item only). The ‘distress’ sub-
scale measures the impact that voices have on the indi-
vidual. The measure has established psychometric
properties.
Hamilton Programme for Schizophrenia Voices
Questionnaire (HPSVQ) [25] Negative Impact Scale –
HPSVQ is a 9-item self-report measure of the phenom-
enology and negative impact of voice-hearing. The
‘negative impact’ subscale has four items rated on a 5-
point (0–4) scale and measures the level of distress and
impact that voices have on the person. The HPSVQ has
been found to have strong concurrent validity (all r > 0.80)
as well as good internal consistency (all α > 0.82) in psych-
osis patients [37].
Clinical measures – Secondary
Secondary outcomes will evaluate: (1) mental health
problems commonly experienced by people with
psychosis (anxiety and depression (Hospital Anxiety and
Depression Scale) [38] and paranoia (Paranoid Thoughts
Scale) [39]); (2) variables that have been associated with
the impact of voice-hearing (negative beliefs about the
self (Self Scale of the Brief Core Schema Scale) [40],
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negative beliefs about voices (Beliefs About Voices
Questionnaire – Revised) [41] and negative relating to
voices (Voice and You) [42] and other people (Persons
Relating to Others Questionnaire) [43]; and (3) a range
of personal and social recovery-oriented outcomes (goals
for the outcome of CBTp (CHOICE – short form) [44],
the positive impact of voices (Voice Impact Scale) [45],
engagement in meaningful activity (Work and Social
Adjustment Scale) [46] and social functioning (Social
and Occupational Functioning Scale) [47].
Process measures
Process measures will evaluate the quality of the
therapeutic relationships (Scale to Assess Therapeutic
Relationships) [48] and participants’ expectations for
therapy (Therapy Credibility and Expectancy
Questionnaire) [49].
Health economic measures
The EuroQol 5 dimensions, 5 levels health survey (EQ-
5D-5 L) [50] – is a standardised instrument used as a
measure of health-related quality of life that can be used
in a wide range of health conditions and treatments. The
descriptive system comprises five dimensions: mobility,
self-care, usual activities, pain/discomfort and anxiety/
depression. Each dimension has five levels: no problems,
slight problems, moderate problems, severe problems
and extreme problems.
The Client Service Receipt Inventory (CSRI-UK) [31] –
is a well-validated adaptable research instrument used in
mental health settings to collect information on health,
social and voluntary service utilisation, informal care, ac-
commodation, other public services (e.g. police) and pri-
vate out-of-pocket expenses incurred. Its primary
purpose is to allow resource-use patterns to be described
and costs to be estimated.
The Short Form 12 (SF-12) [51] – this generic health
survey captures information about functional health and
well-being from the patient’s point of view.
Plans to promote participant retention and complete
follow-up {18b}
Efforts will be made to engage all participants in follow-
up assessments. RAs will flexibly engage patients, offer-
ing appointments at times and locations which best suit
participants and offering shorter and split assessment
sessions as needed. Participants will be offered reim-
bursement of £20 per assessment point (i.e. baseline, 16
and 28 weeks) and travel expenses will be made avail-
able. Retention rates will be monitored by the trial man-
ager at least weekly and the research team on a monthly
basis throughout the trial. The Lived Experience Advis-
ory Panel (LEAP) will be asked to provide consultation
regarding retention rates as part of their oversight role.
Data management {19}
Data collection and analysis will be supervised by the Trial
Statistician. The management of the data will be a standing
item on the agenda of the monthly meeting of the research
team. All members of the research team and any other
individuals from collaborating Trusts or Universities
involved in collecting, inputting, processing, using and
sharing data will have had Information Governance
training.
Confidentiality {27}
The minimum amount of personal information needed
to conduct the study will be obtained from participants.
Personal and research data will be stored securely on
NHS premises. Physical data, such as consent forms, will
be locked in filing cabinets on NHS premises accessible
only to members of the research team. Electronic data
will be stored securely in password-protected or
encrypted files on NHS computers accessible only to
members of the research team. All research data will be
fully anonymised and will be stored separately to per-
sonal data. A link file will allow for participant research
data to be identified. This link file will be a password-
protected file accessible only by members of the trial
team within each research site and the trial manager.
This file will be securely destroyed following the end of
the study. Quantitative and qualitative data will be ap-
propriately aggregated in any publications arising from
the trial to protect participant anonymity during and
after the trial has ended.
Statistical methods
Statistical methods for primary and secondary outcomes {20a}
Analyses will be based on the intention-to-treat approach.
All clinical outcomes will be summarised using descriptive
statistics at pre-randomisation (T0), at 16 weeks (T1) and at
28 weeks (T2) for each arm (GiVE, SC and TAU) of the
study. Next, 95 and 75% confidence intervals [51] will be
created for between-group mean differences after adjust-
ment for the baseline scores using analysis of covariance
(ANCOVA) for the following comparisons: GiVE vs TAU;
GiVE vs SC; and TAU vs SC. There will be no hypothesis
testing.
Analysis will be conducted using a linear mixed model
with a random effect for individual with fixed effects for
treatment group (TAU, GiVE and SC) and time (16 and
28 weeks); baseline score and site will be entered as
covariates. Contrasts will be used to compare groups
(GiVE vs TAU, GiVE vs SC and TAU vs SC) at T1 and
T2. 95 and 75% confidence intervals [25] for between-
group mean differences will be created for all estimates
of unstandardised effect size.
Standardised (Cohen’s d) effect sizes for each outcome
will be calculated by dividing the between-group
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unstandardised effect by the baseline pooled standard
deviation. The level of missing data will be summarised
for each outcome and reported for each time point.
Two potential primary outcomes – the Distress scale
of PSYRATS and the Negative Impact scale of the
HPSVQ – are being explored in this feasibility study. In
addition to the analyses for all clinical outcomes, the
between-groups differences for these two variables will
be assessed in the context of:
 Whether the minimal clinically important difference
(MCID) is contained within the 95% confidence
intervals where:
PSYRATS Distress scale of MCID is a 3-point
reduction
HPSVQ Negative Impact scale MCID is a 2-
point reduction
 The level of missing data
 Popularity of the outcome in the literature
 Any other relevant information generated by the
process evaluation
Methods for additional analyses {20b}
Health economic analysis
An economic evaluation will provide basic information
to facilitate the planning of a definitive, multi-centre
RCT to assess clinical and cost-effectiveness. The re-
source requirements and costs of each arm will be inves-
tigated using trial details on the delivery of GIVE and
SC. Staff time will be costed using national tariffs, inclu-
sive of on-costs and overheads [52]. Participants will be
asked to complete the CSRI-UK at 16 weeks and 28
weeks to record all forms of service use (including activ-
ity classified as usual care), informal care and out-of-
pocket expenses. Information gathered through the
CSRI-UK will be cross-checked for accuracy with mental
health records. Discrepancies between these records will
be recorded and evaluated. Health-related quality of life
(HRQoL) will be recorded at baseline and 16 and 28
weeks using both the EQ-5D-5 L and SF-12 for calcula-
tion of Quality-adjusted Life Years (QALYs) as the latter
may be more sensitive to changes in psychological sta-
tus. Completeness of data will be assessed. Variability in
standard care will be explored, and the use of EQ-5D-5
L and SF-12 compared. Differences in service use be-
tween groups will be investigated for indications of po-
tential savings associated with GiVE that might offset
the intervention costs. The full range of outcomes will
be investigated in a cost consequences framework and a
preliminary cost-effectiveness analysis conducted.
Process evaluation
The process evaluation will be guided by MRC
Guidelines [53] and used to evaluate:
1) Reach of the intervention – the proportion of
eligible participants who are referred and who
accept the offer of therapy, and responses from
referring and non-referring clinicians to a question-
naire designed to explore their decision-making
around referring patients with psychosis to CBT
generally and the GiVE intervention specifically;
2) Implementation of the intervention – what was
delivered in terms of exposure (number of sessions
offered and received by participants) and therapist
adherence to protocol;
3) How the intervention was delivered – qualitative
interviews with the APs delivering GiVE regarding
their experience of the training, manuals,
supervision and intervention delivery;
4) Context – qualitative interviews with clinicians and
managers from referring services, to determine the
potential actions, context (team/service/supervisor
issues), processes, structures and coherence with
standard care which might influence
implementation of the GiVE intervention, including
sense-making, and potential effort, action, commit-
ment, participation and reflection on implementa-
tion of GiVE in routine services;
5) Participant experience – of the research process,
randomisation, outcomes, potential mechanisms
and mediators, and therapy.
Descriptive data will be used to summarise reach and
implementation of the intervention. Qualitative data
from the process evaluation interviews will be analysed
using thematic analysis [54]; this method will be used to
highlight the key themes across interviews in relation to
the research questions. These themes will be used to
adapt the study design, manuals, training, supervision
and intervention delivery where necessary before
proceeding to a definitive trial. In addition, the
qualitative data will be used to develop both: (1) a
system-based logic model for the implementation of the
trial and subsequent therapy; and (2) a process-based
logic model of the potential mechanisms from therapy
experience to outcomes. These will be further refined in
the future definitive RCT.
Oversight and monitoring
Composition of the Trial Steering Committee (TSC) {5d}
Medical Research Council Guidelines on Good Clinical
Practice in Clinical Trials [55] informed the constitution
of the TSC, which includes an independent chair,
independent experts and lay members.
The scientific integrity of the trial will be overseen by
the TSC. The TSC will also serve the functions of a Data
Monitoring and Ethics Committee (DMEC), as a
combined TSC and DMEC is appropriate within the size
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and scope of the present feasibility trial, including
oversight of the safety and data integrity of the trial.
A separate LEAP will provide Patient and Public
Involvement (PPI) oversight of the trial. The LEAP will
consult at regular intervals throughout the trial
(approximately six meetings in total) and will advise on
issues relating to design, delivery, interpretation of
findings, dissemination and preparation for a
future definitive RCT. Prior to the submission of the
grant application for the current study, the LEAP
reviewed the differences between the training and role of
clinical psychologists (who delivered GiVE in our initial
pilot RCT) and APs (who will deliver GiVE in the
current study) and emphasised the need for APs to have
experience of working with people with psychosis. This
became an essential criterion for appointment to the AP
post.
Adverse event (AE) reporting and harms {22}
Any unfavourable and unintended sign, symptom or
illness that develops or worsens during the period of
the study will be classified as an AE, whether or not
it is considered to be related to the study treatment.
Adverse events will include: an exacerbation of a pre-
existing illness; an increase in the frequency or inten-
sity of a pre-existing episodic event or condition; a
condition that is detected after trial intervention ad-
ministration; and continuous persistent disease or a
symptom present at baseline that worsens following
administration of the trial treatment – and may be
expected or unexpected. Serious adverse events
(SAEs) are those considered to be life-threatening,
resulting in death, requiring inpatient hospitalisation
or prolongation of existing hospitalisation, resulting in
significant or persistent incapacity/disability or a birth
defect or congenital abnormality. The number (events
and individuals) and nature of all events (AEs and
SAEs) reported to blind and unblind members of the
research team will be recorded.
The period for AE reporting will be following the
signing of the study consent form until last follow-up as-
sessment 28 weeks after randomisation. All AEs will be
recorded and reviewed by the chief investigator. If an AE
is considered to be serious (an SAE), it will be reviewed
for causality and expectedness by an independent rater
and the sponsor’s representative. The TSC will be in-
formed of the number, nature and review outcome for
all SAEs and will be asked to recommend any necessary
actions. SAEs will be reported to the NHS Research Eth-
ics Committee as appropriate.
Dissemination plans {31a}
Trial findings will be disseminated in scientific
publications, including feasibility outcomes and process
evaluation findings. Findings will be disseminated to
participants’ and patient organisations. LEAP members
will participate in dissemination including use of social
media, producing leaflets for wide distribution and
submitting a summary of findings to a non-academic
journal. Findings will be presented at patient events and
at local, national and international conferences.
Discussion
CBTp is an evidence-based psychological therapy recom-
mended for psychosis patients within the UK. However,
only a minority of patients are offered CBTp. Limited re-
sources have been cited as a prominent reason for this
lack of access, leading to calls for shorter forms of CBTp
to be developed that can be delivered by briefly trained
therapists.
We have responded to this call by developing a brief
and targeted form of CBTp for distressing voices –
Guided, self-help intervention for Voices (GiVE). We
have generated preliminary evidence for the effectiveness
of GiVE when delivered by highly trained therapist (clin-
ical psychologists). The next step is to evaluate the ex-
perience of stakeholders when GiVE is delivered by
Table 1 Protocol changes
Protocol version Details of change
Version 2 (2 Jan
2019)
Addition of exclusion criterion for patients currently detained in hospital under a section of the Mental Health Act.
Addition of Test of Premorbid Functioning as relevant to eligibility assessment of presence of serious learning disability.
Addition of statement of intent to audio-record participant assessments.
Version 3 (17 Apr
2019)
Reduction of lower age threshold for inclusion from 18 years to 16 years.
Removal of statement of intent to audio-record participant assessments.
Version 4 (14 Aug
2019)
Addition of questionnaire for referring and non-referring clinicians to explore their decision-making around referring patients with
psychoRemoval of statement of intentsis to CBT generally and the GiVE intervention specifically as part of process evaluation.
Revision of qualitative interview with a subsample of therapy participants to explore their experiences of therapy participation,
outcomes, and potential mechanisms of change as part of process evaluation.
Version 5 (25 Sept
2019)
Typographical correction regarding list of participant assessments.
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briefly trained therapists (APs). The current study will
explore the feasibility of conducting this evaluation in
the form of a pragmatic, three-arm, parallel-group, su-
periority 1:1:1 RCT comparing GiVE to an active control
intervention (SC) and TAU.
CBTp offered in these less resource-intensive forms
has the potential to generate benefits for: (1) individual
patients (reduced distress and enhanced recovery and
enhanced quality of life); (2) service-level patient benefit
(increased access to evidence-based psychological ther-
apies); and (3) economic benefits to the NHS (in terms
of the reduced use of mental health inpatient services).
Trial status
Recruitment to the trial commenced in February 2019
(study protocol – version 1, dated 5 November 2018). At
present, recruitment and data collection will continue
until July 2020.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-4181-y.
Additional file 1: Participant Information Sheet (Patient participants).
Additional file 2: Consent Form (Patient participants).
Abbreviations
AP: Assistant psychologist; CBTp: Cognitive Behaviour Therapy for psychosis;
CC: Care co-ordinator; CHOICE: CHoice of Outcome In Cbt for psychosEs;
CSRI: Client Service Receipt Inventory; DMEC: Data Monitoring and Ethics
Committee; DSM: Diagnostic and Statistical Manual for Mental Disorders;
GiVE: Guided self-help CBT intervention for Voices; HPSVQ: Hamilton
Programme for Schizophrenic Voices Questionnaire; HRQoL: Health-related
quality of life; MCID: Minimum clinically important difference; MRC: Medical
Research Council; NHS: National Health Service; NICE: National Institute for
Health and Care Excellence; NIHR: National Institute for Health Research;
PIS: Participant Information Sheet; PSYRATS: Psychotic Symptoms Rating
Scale; QALYs: Quality-adjusted Life Years; RA: Research assistant;
RCT: Randomised controlled trial; SC: Supportive Counselling; SCID-
5: Structured Clinical Interview for DSM-5 disorders; SF-12: Short Form12
health survey; TAU: Treatment as usual; TOPF-UK: Test of Premorbid
Functioning–UK; TSC: Trial Steering Committee
Acknowledgements
We would like to acknowledge the significant contribution to the study that
is being made by the APs (Emogen Campbell, Sophie Green, Debbie
Sheffield and Sasha Stone) and RAs (Maisha Murshed and Suzanne
Neumann). We also appreciate the advice and assistance that is being
offered by Becky Whitfield, Peter Garwood, Jake Ellwood, Tina Perry and our
Lived Experience Consultants.
Authors’ contributions {31b}
MH is the CI of the study and accountable for all aspects of the work in
ensuring that questions related to the accuracy or integrity of any part of
the work are appropriately investigated and resolved. MH, BC and CB took
responsibility for the main drafting of the manuscript. All authors made
substantial contributions to conception and design. All authors have been
involved in drafting the manuscript or revising it critically for important
intellectual content. All authors read and approved the final manuscript.
Funding {4}
This paper presents independent research funded by the National Institute
for Health Research (NIHR) under its Research for Patient Benefit (RfPB)
Programme (Grant Reference Number PB-PG-0317-20029). The views
expressed are those of the author(s) and not necessarily those of the NIHR or
the Department of Health and Social Care.
Availability of data and materials {29}
Not currently applicable. The fully anonymised datasets generated and/or
analysed (and associated statistical code) during the current study will be
available from the corresponding author on reasonable request following
the publication of results.
Ethics approval and consent to participate {24}
The study is sponsored by Sussex Partnership NHS Foundation Trust which
will provide at least annual monitoring and audit of the trial and governance
procedures. NHS Research Ethics Committee (London – Surrey, reference
number 18/LO/ 2091), Health Research Authority and local Research
Governance (at both sites) approval were granted before the
commencement of the trial (study protocol – version 1, dated 5 November
2018 (see Table 1 for approved amendments to protocol)). Participants will
provide written informed consent prior to the completion of any study
procedures. The sponsor played no part in study design; collection,
management, analysis and interpretation of data; writing of the report; and
the decision to submit the report for publication.
Competing interests {28}
There is a potential conflict of interest as some members of the research
team (MH, CS and CH) are also authors on the self-help book and/or pub-
lished workbook being used within the GiVE intervention. Therefore, the re-
search team agrees to publish the results of this feasibility trial, irrespective
of the findings.
Author details
1School of Psychology, University of Sussex, Brighton BN1 9RH, UK. 2Research
and Development Department, Sussex Partnership NHS Foundation Trust,
Hove BN3 7HZ, UK. 3Research and Development Department, Pennine Care
NHS Foundation Trust, 225 Old St, Ashton-under-Lyne OL6 7SR, UK. 4Faculty
of Biology, Medicine and Health, University of Manchester, Manchester M13
9PL, UK. 5Brighton and Sussex Medical School, University of Sussex, Brighton
BN1 9RH, UK. 6School of Biosciences and Medicine, University of Surrey,
Guildford GU2 7XH, UK. 7Social Sciences Department, University of
Westminster, London W1W 6UW, UK. 8University of Sussex and Sussex
Partnership NHS Foundation Trust, Brighton BN3 7HZ, UK.
Received: 4 January 2020 Accepted: 18 February 2020
References
1. van der Gaag M, Valmaggia LR, Smit F. The effects of individually tailored
formulation- based cognitive behavioural therapy in auditory hallucinations
and delusions: a meta-analysis. Schizophr Res. 2014;156:30–7.
2. Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C. Cognitive
behaviour therapy for schizophrenia. Cochrane Database Syst Rev. 2004;4:
CD000524 https://doi.org/10.1002/14651858.CD000524.pub2. Accessed 30
Jan 2020.
3. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for
schizophrenia: effect sizes, clinical models, and methodological rigor.
Schizophrenia Bull. 2008;34:523–37.
4. National Institute for Health and Care Excellence. Psychosis and
schizophrenia in adults: treatment and management (CG178). London:
National Institute for Health and Care Excellence; 2014. Available at http://
guidance.nice.org.uk/CG178. Accessed 30 Jan 2020.
5. Haddock G, Eisner E, Boone C, Davies G, Coogan C, Barrowclough C. An
investigation of the implementation of NICE-recommended CBT
interventions for people with schizophrenia. J Ment Health. 2014;23:162–5.
6. The Royal College of Psychiatrists. National Clinical Audit of Psychosis –
National Report for the Core Audit. London: Healthcare Quality
Improvement Partnership; 2018. https://www.hqip.org.uk/wp-content/
uploads/2018/07/NCAP-National-report-for-core-audit-2018-FINAL.pdf.
Accessed 30 Jan 2020.
7. Ince P, Haddock G, Tai S. A systematic review of the implementation of
recommended psychological interventions for schizophrenia: rates, barriers,
and improvement strategies. Psychol Psychother. 2016;89:324–50.
Hayward et al. Trials          (2020) 21:302 Page 12 of 14
8. NHS England. Five year forward view for mental health. 2014. https://www.
england.nhs.uk/wp-content/uploads/2016/02/Mental-Health-Taskforce-FYFV-
final.pdf. Accessed 30 Jan 2020.
9. NHS. The NHS long term plan. 2019. https://www.longtermplan.nhs.uk/.
Accessed 5 Oct 2019.
10. Hazell C, Hayward M, Cavanagh K, Strauss C. A systematic review and meta-
analysis of low intensity CBT for psychosis. Clin Psychol Rev. 2016;45:183–92.
11. Birchwood M, Trower P. The future of cognitive-behavioural therapy for
psychosis: not a quasi-neuroleptic. Brit J Psychiat. 2006;188:107–8.
12. Freeman D, Dunn G, Startup H, Pugh K, Cordwekk J, Mander H, et al. Effects
of cognitive behaviour therapy for worry on persecutory delusions in
patients with psychosis (WIT): a parallel, single-blind, randomised controlled
trial with a mediation analysis. Lancet Psychiat. 2015;380:305–13.
13. Waller H, Emsley R, Freeman D, Bebbington P, Dunn R, Fowler D, et al.
Thinking Well: a randomised controlled feasibility study of a new CBT
therapy targeting reasoning biases in people with distressing persecutory
delusional beliefs. J Behav Ther Exp Psy. 2015;48:82–9.
14. Craig TKJ, Rus-Calafell M, Ward T, Leff JP, Huckvale M, Howarth E, et al.
AVATAR Therapy for auditory verbal hallucinations in psychosis patients: a
single-blind randomized controlled trial. Lancet Psychiat. 2018;5:31–40.
15. van der Gaag M, Van Oosterhout B, Daalman K, Sommer IE, Korrelboom K.
Initial evaluation of the effects of competitive memory training (COMET) on
depression in schizophrenia-spectrum patients with persistent auditory
verbal hallucinations: a randomized controlled trial. Brit J Clin Psychol. 2012;
5:158–71.
16. Turkington D, Kingdon D, Turner T. Effectiveness of a brief cognitive-
behavioural therapy intervention in the treatment of schizophrenia. Brit J
Psychiat. 2002;180:523–7.
17. Turkington D, Kingdon D, Rathod S, Hammond K, Pelton J, Mehta R.
Outcomes of an effectiveness trial of cognitive-behavioural intervention by
mental health nurses in schizophrenia. Brit J Psychiat. 2006;189:36–40.
18. Harding H, Landau S, Fornells-Ambrojo M, Jolley S, McCrone P, Halkoree R,
et al. Improving implementation of evidence-based practice for people with
psychosis through training the wider workforce: results of the GOALS
randomized controlled trial. J Behav Ther Exp Psy. 2018;59:121–8.
19. Jolley S, Onwumere J, Kuipers E, Craig T, Moriarty A, Garety P. Increasing
access to psychological therapies for people with psychosis: predictors of
successful training. Behav Res Ther. 2013;50:457–62.
20. Richards DA, Ehlers D, McMillan D, Taylor R, Byford S, Warren F, et al. Cost
and outcome of behavioural activation versus cognitive behaviour therapy
for depression (COBRA): a randomised, controlled, non-inferiority trial.
Lancet. 2016;388:871–80.
21. Hayward M, Strauss C, Kingdon D. Overcoming distressing voices (2nd ed).
London: Constable & Robinson; 2018.
22. Hazell CM, Hayward M, Cavanagh K, Jones A-M, Strauss C. Guided self-help
cognitive behavioral intervention for Voices (GiVE): study protocol for a pilot
randomized controlled trial. Trials. 2016;17:351.
23. Hazell C, Hayward M, Cavanagh K, Jones A-M, Strauss C. Guided self-help
cognitive-behaviour Intervention for Voices (GiVE): results from a pilot
randomised controlled trial. Schizophr Res. 2017;195:441–7.
24. May CR, Mair F, Finch T, MacFarlane A, Dowrick C, Treweek S, et al.
Development of a theory of implementation and integration: Normalization
Process Theory. Implement Sci. 2009;4:29.
25. Van Lieshout RJ, Goldberg JO. Quantifying self-reports of auditory verbal
hallucinations in person with psychosis. Can J Beh Sci. 2007;39:73–7.
26. First MB, Williams JBW, Karg RS, Spitser RL. Structured clinical interview
for DSM-5 disorders (SCID-5). Washington, DC: American Psychiatric
Association; 2016.
27. Wechsler D. The Test of Premorbid Functioning (TOPF). San Antonio: The
Psychological Corporation; 2011.
28. Hazell C, Hayward M, Strauss C, Kingdon D. An introduction to self-help for
distressing voices. London: Robinson; 2018.
29. Craig, C. Personal communication. Consultant Psychiatrist. 11 July 2017.
30. Haddock G, Devane S, Bradshaw T, McGovern J, Tarrier N, Kinderman P,
et al. An investigation into the psychometric properties of the
Cognitive Therapy Scale for Psychosis (CTS-Psy). Behav Cogn Psychoth.
2001;29:221–34.
31. Thornicroft G, Becker T, Knapp M, Knudsen HC, Schene A, Tansella M. CSRI
European version. In: International outcome measures in mental health
(Chapter 9). Trowbridge, Wiltshire: Royal College of Psychiatrists; 2006.
32. Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating a sample
size for a pilot randomised trial to minimise the overall trial sample size for
the external pilot and the main trial for continuous outcome variable. Stat
Methods Med Res. 2016;25:1057–73.
33. Sim J, Lewis M. The size of a pilot study for a clinical trial should be
calculated in relation to considerations of precision and efficiency. J Clin
Epidemiol. 2012;65:301–8.
34. Teare MD, Dimairo M, Shepherd N, Hayman A, Whitehead A, Walters SJ.
Sample size requirements to estimate key design parameters from
external pilot randomised controlled trials: a simulation study. Trials.
2014;15:264.
35. Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure
dimensions of hallucinations and delusions: the PSYchotic symptom RATing
Scales (PSYRATS). Psychol Med. 1999;29:879–89.
36. Woodward TS, Jung K, Hwang H, Yin J, Taylor L, Menon M, et al. Symptom
dimensions of the psychotic symptom rating scales in psychosis: a multisite
study. Schizophr Bull. 2014;40:265–74.
37. Kim SH, Jung HY, Hwang SS, Chang JS, Kim Y, Ahn YM, Kim YS. 2010. The
usefulness of a self-report questionnaire measuring auditory verbal
hallucinations. Prog Neuro-Psychoph. 2010;6(34):968–73.
38. Zigmund AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta
Psychiat Scand. 1983;67:361–70.
39. Green C, Freeman D, Kuipers E, Bebbington P, Fowler D, Dunn G, et al.
Measuring ideas of persecution and reference: the Green et al. Paranoid
Thought Scales (G-PTS). Psychol Med. 2008;38:101–11.
40. Fowler D, Freeman D, Smith B, Kuipers E, Bebbington P, Bashworth H, et al.
The Brief Core Schema Scale (BCSS): psychometric properties and
associations with paranoia and grandiosity in non-clinical and psychosis
samples. Psychol Med. 2006;36:749–59.
41. Chadwick P, Lees S, Birchwood M. The revised Beliefs About Voices
Questionnaire (BAVQ-R). Brit J Psychiat. 2000;177:229–32.
42. Hayward M, Denney J, Vaughan S, Fowler D. The Voice and You:
development and psychometric evaluation of a measure of relationships
with voices. Clin Psychol Psychot. 2008;15:45–52.
43. Birtchnell J, Hammond S, Horn E, De Jong C, Argyroula K. A cross national
comparison of a shorter version of the Person’s Relating to Others
Questionnaire. Clin Psychol Psychot. 2013;20:36–48.
44. Greenwood KE, Sweeney A, Williams S, Garety P, K CHoice of Outcome In
Cbt for psychosesuipers E, Scott J, et al. CHoice of Outcome In Cbt for
psychosEs (CHOICE): the development of a new service user-led outcome
measure of CBT for psychosis. Schizophr Bull. 2010;36:126–35.
45. Strauss C. Personal communication. Consultant Clinical Psychologist. 10 Aug
2018.
46. Mundt JC, Marks IM, Shear MK, Greist JM. The Work and Social Adjustment
Scale: a simple measure of impairment in functioning. Brit J Psychiat. 2002;
180:461–4.
47. Rybarczyk B. Social and Occupational Functioning Assessment Scale
(SOFAS). In: Kreutzer JS, DeLuca J, Caplan B, editors. Encyclopedia of clinical
neuropsychology. New York: Springer; 2011.
48. McGuire-Snieckus R, McCabe R, Catty J, Hansson L, Proebe S. A new scale to
assess the therapeutic relationship in community mental health care: STAR.
Psychol Med. 2007;37:85–95.
49. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/
expectancy questionnaire. J Beh Ther Exp Psy. 2000;31:73–86.
50. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72.
51. Ware JE, Kosinki M, Keller SD. SF-12: How to score the SF-12 Physical and
Mental Health Summary Scales. Boston: The Health Institute, New England
Medical Centre; 1995.
52. Curtis L, Burns A. Unit costs of health and social care 2018: Personal Social
Services Research Unit, University of Kent; 2019. https://www.pssru.ac.uk/
project-pages/unit-costs/unit-costs-2019/. Accessed 30 Jan 2020.
53. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process
evaluation of complex interventions: Medical Research Council guidance.
Brit Med J. 2015;350:h1258.
54. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol.
2006;3:77–101.
55. Medical Research Council (UK). Guidelines for Good Clinical Practice in
clinical trials. London: MRC; 1998. https://research.ncl.ac.uk/trauma.stitch/
Information%20For%20Centres/Guidelines_for_Good_Clinical_Practice.pdf.
Accessed 30 Jan 2020.
Hayward et al. Trials          (2020) 21:302 Page 13 of 14
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Hayward et al. Trials          (2020) 21:302 Page 14 of 14
